Targeted radiation plus osimertinib for brain metastases from EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung adenocarcinoma that has an EGFR mutation (either exon 19 deletion or L858R).
- You have at least one brain metastasis that is causing symptoms, with 1 to 10 brain tumors that need higher radiation doses, and at least one tumor measures 10 mm or larger on a scan.
- You have not had any previous cancer treatment (like chemotherapy, radiation, or targeted therapy) for your lung cancer.
- Your overall health is good enough to perform daily activities (ECOG score 0-2) and your life expectancy is at least 12 weeks.
- Your organs (bone marrow, liver, kidneys, heart) are working well based on recent blood tests and an ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial tests if adding stereotactic radiosurgery (focused radiation) to standard drug therapy is safe and effective for people with EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to improve control of brain metastases while continuing targeted therapy.
This study tests whether adding a precise, high-dose type of radiation (called SBRT or SRS) to the targeted therapy pill osimertinib can better control lung cancer that has an EGFR mutation. If you have had a good response to osimertinib but still have a few remaining tumors, this combination may help improve outcomes.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
Hear when a new Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.